Clinical Trial: A Proof-Of-Concept (POC) Study of SFG-02 Transdermal Formulation in Participants With Underactive Bladder (UAB)

U.S., Oct. 31 -- ClinicalTrials.gov registry received information related to the study (NCT07906106) titled 'A Proof-Of-Concept (POC) Study of SFG-02 Transdermal Formulation in Participants With Underactive Bladder (UAB)' on Oct. 21.

Brief Summary: The objective of this POC (Phase 2a) study is to evaluate the effect on Bladder Voiding Efficiency (BVE) as well as safety of SFG-02 transdermal formulation in participants with UAB.

Participants will:

* Apply the study patches every day for 12 weeks and wear each patch for a full day

* Visit the clinic once every 2 to 4 weeks for checkups and tests

* Keep diaries about their bladder symptoms and the times they change their study patches

Study Start Date: Aug. 22

Study Type: INTERVENTIONAL...